These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 20164224)
1. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. Kwon SY; Park YK; Ahn SH; Cho ES; Choe WH; Lee CH; Kim BK; Ko SY; Choi HS; Park ES; Shin GC; Kim KH J Virol; 2010 May; 84(9):4494-503. PubMed ID: 20164224 [TBL] [Abstract][Full Text] [Related]
2. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection. Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206 [TBL] [Abstract][Full Text] [Related]
3. Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance. Ahn SH; Kim DH; Lee AR; Kim BK; Park YK; Park ES; Ahn SH; Shin GC; Park S; Kang HS; Rhee JK; Yang SI; Chong Y; Kim KH PLoS One; 2015; 10(8):e0136728. PubMed ID: 26322642 [TBL] [Abstract][Full Text] [Related]
4. [Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases]. Lee HJ; Eun JR; Lee CH; Hwang JS; Suh JI; Kim BS; Jang BK Korean J Hepatol; 2009 Jun; 15(2):179-92. PubMed ID: 19581770 [TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: Analysis of a large cohort of Chinese patients. Chen R; Liu Y; Luo D; Si L; Huang B; Wang J; Li X; Cheng F; Xu D; Duan C Antiviral Res; 2020 Aug; 180():104852. PubMed ID: 32569703 [TBL] [Abstract][Full Text] [Related]
6. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. Park ES; Lee AR; Kim DH; Lee JH; Yoo JJ; Ahn SH; Sim H; Park S; Kang HS; Won J; Ha YN; Shin GC; Kwon SY; Park YK; Choi BS; Lee YB; Jeong N; An Y; Ju YS; Yu SJ; Chae HB; Yu KS; Kim YJ; Yoon JH; Zoulim F; Kim KH J Hepatol; 2019 Jun; 70(6):1093-1102. PubMed ID: 30794889 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors. Niu C; Bao H; Tolstykh T; Micolochick Steuer HM; Murakami E; Korba B; Furman PA Antivir Ther; 2010; 15(3):401-12. PubMed ID: 20516559 [TBL] [Abstract][Full Text] [Related]
8. Resistant mutations within the hepatitis B virus reverse transcriptase sequence in treatment failure patients with chronic HBV infection in Vietnam. Nguyen TK; Van Le D J Glob Antimicrob Resist; 2023 Jun; 33():35-41. PubMed ID: 36849052 [TBL] [Abstract][Full Text] [Related]
9. [Detection of resistance mutations in chronic hepatitis B patients receiving antiviral therapy for over one year]. Aydoğan S; Ergünay K; Balaban Y; Alp A; Simşek H; Tatar G; Hasçelik G; Us D Mikrobiyol Bul; 2013 Jul; 47(3):472-81. PubMed ID: 23971924 [TBL] [Abstract][Full Text] [Related]
10. Investigation of hepatitis B virus (HBV) rtS78T/sC69* mutation in a large cohort of chronic HBV-infected patients with nucleoside/nucleotide analogue treatment. Luo D; Liu Y; Chen R; Niu M; Liu L; Li X; Li Q; Huang B; Wang J; Xu D; Lin S Antiviral Res; 2019 Oct; 170():104579. PubMed ID: 31398372 [TBL] [Abstract][Full Text] [Related]
11. Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients. Liu Y; Liu W; Li X; Xu Z; Wang X; Li C; Chen L; Xin S; Xu D Antivir Ther; 2014; 19(6):551-8. PubMed ID: 24710668 [TBL] [Abstract][Full Text] [Related]
12. Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance? Lee GH; Aung MO; Dan YY; Lee YM; Mak B; Low HC; Lim K; Thwin MA; Tan PS; Lim SG J Med Virol; 2013 Jan; 85(1):26-33. PubMed ID: 23023992 [TBL] [Abstract][Full Text] [Related]
13. Acute hepatitis B infection associated with drug-resistant hepatitis B virus. Xu Z; Liu Y; Xu T; Chen L; Si L; Wang Y; Ren X; Zhong Y; Zhao J; Xu D J Clin Virol; 2010 Aug; 48(4):270-4. PubMed ID: 20580309 [TBL] [Abstract][Full Text] [Related]
14. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir. Zaaijer HL; Takkenberg RB; Weegink CJ; Rebers SP; Menting S; Reesink HW; Schinkel J; Molenkamp R J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408 [TBL] [Abstract][Full Text] [Related]
15. rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B. Liu LJ; Wang JH; Du SC; Tian JH; Yang RF; Wei L J Viral Hepat; 2010 Mar; 17 Suppl 1():66-72. PubMed ID: 20586936 [TBL] [Abstract][Full Text] [Related]
16. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene. Ahn SH; Park YK; Park ES; Kim JH; Kim DH; Lim KH; Jang MS; Choe WH; Ko SY; Sung IK; Kwon SY; Kim KH J Virol; 2014 Jun; 88(12):6805-18. PubMed ID: 24696492 [TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898 [TBL] [Abstract][Full Text] [Related]
18. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B. Cha CK; Kwon HC; Cheong JY; Cho SW; Hong SP; Kim SO; Yoo WD J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409 [TBL] [Abstract][Full Text] [Related]
19. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Corsa AC; Liu Y; Flaherty JF; Mitchell B; Fung SK; Gane E; Miller MD; Kitrinos KM Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2106-12.e1. PubMed ID: 24929235 [TBL] [Abstract][Full Text] [Related]
20. Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. Shirvani-Dastgerdi E; Winer BY; Celià-Terrassa T; Kang Y; Tabernero D; Yagmur E; Rodríguez-Frías F; Gregori J; Luedde T; Trautwein C; Ploss A; Tacke F J Hepatol; 2017 Aug; 67(2):246-254. PubMed ID: 28392234 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]